Geranylgeraniol prevents statin-induced skeletal muscle fatigue without causing adverse effects in cardiac or vascular smooth muscle performance

The administration of geranylgeranyl pyrophosphate (GGPP) (or its precursor, geranylgeraniol) has been shown by several in vitro studies to be capable of abrogating statin-induced myotoxicity. Nonetheless, the potential of GGPP repletion to prevent statin-associated muscle symptoms (SAMS) in vivo is yet to be investigated. Therefore, this study aimed to evaluate the ability of geranylgeraniol (GGOH) to prevent SAMS in rodents. Female Wistar rats (12 weeks of age) were randomised to one of four treatment groups: control, control with GGOH, simvastatin or simvastatin with GGOH.
Source: Translational Research - Category: Research Authors: Source Type: research